Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral THU-Decitabine in Relapsed/Refractory MDS
NCT07006025Phase 1Recruiting
- Sponsor
- Treebough Therapies
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of decitabine in myelodysplastic syndrome (MDS), sponsored by Treebough Therapies. Primary endpoints: White Blood Cell Count at 24 weeks and Platelet Count at 24 weeks. Started Jun 2025; status: recruiting.
02
Drugs
decitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07006025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07006025.